Apellis Pharmaceuticals (APLS)
(Real Time Quote from BATS)
$36.22 USD
+0.81 (2.29%)
Updated Jul 5, 2024 03:55 PM ET
After-Market: $36.24 +0.02 (0.06%) 4:14 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Apellis Pharmaceuticals, Inc. [APLS]
Reports for Purchase
Showing records 1 - 20 ( 289 total )
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pegcetacoplan Demonstrated Sustained Efficacy In C3G and IC-MPGN; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Swapping Sixth Street Credit Facility For SFJ; Adjusting Model
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Syfovre Continues to Deliver Upside to Numbers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Competitive Headwinds Getting Real In 2024? Will See
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Competitive Headwinds Getting Real In 2024? Will See
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Reset on MAA Review Creates Opportunity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CHMP Re-Examination Calls For Re-Do? EMA Resetting Syfovre Evaluation
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Conversation With Apellis Pharmaceuticals Management; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
With Vasculitis Fading to Black, the Growth Story Comes Into Focus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D